시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 우르소데옥시콜산 시장 보고서(2025년)
Ursodeoxycholic Acid Global Market Report 2025
상품코드 : 1769784
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 우르소데옥시콜산 시장 규모는 향후 수년간 급성장이 예상됩니다. 성장의 원동력이 되는 것은 생활 습관과 관련된 건강 문제의 부담 증가, 간 비호 약에 대한 의존 증가, 장기간 간 질환 치료에 대한 요구 증가, 담즙산 유도체에 초점을 맞춥니다. 향후 몇 년간의 주요 시장 동향으로서는 표적 약물전달법의 발전, UDCA와 다른 간 보호 물질과의 병용, 새로운 약제 제제 전략, 담즙산 아날로그의 개발, 간 재생을 목적으로 한 RNA 치료법 출현 등이 있습니다.

간질환의 유병률 증가는 향후 수년간 우르소데옥시콜산 시장의 확대를 견인할 것으로 예측됩니다. 장기간의 과도한 음주는 간에 큰 피해를 줄 수 있기 때문에 간 관련 질병 증가의 주요 요인 중 하나는 알코올 비용 증가입니다.우르소데옥시콜산은 담즙의 흐름을 촉진하고 독성 담즙산의 수준을 저하시킴으로써 간질환의 치료에 중요한 역할을 하고 있습니다. 2024년 4월, Office for Health Improvement and Disparities는 간 질환으로 인한 조기 사망자 수를 남성 6,664명, 여성 3,929명으로 보고했습니다.

우르소데옥시콜산(UDCA) 시장의 주요 기업들은 간질환, 특히 담즙 울체성 간장애의 치료를 개선하기 위해 담즙산 유도체와 같은 고급 치료법의 개발을 점점 더 추진하고 있습니다. 담즙산 유도체는 간 기능을 지원하고 다양한 간 질환을 관리하기 위해 고안된 담즙산의 화학적 변형 형태입니다. 2024년 11월, Nora Pharma Inc.는 원발성 담즙성 담관염(PBC)을 포함한 담즙 울체성 간 질환의 치료를 목적으로 한 Ursodiol(우르소데옥시콜산)의 제네릭 의약품을 발매했습니다. 특히 질병 경과의 초기에 투여함으로써 간장애의 진행을 억제하는데 사용됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

Ursodeoxycholic acid (UDCA) is a naturally occurring bile acid produced in small quantities by the human liver. It is utilized as a medication for dissolving specific types of gallstones and for treating various liver and gallbladder conditions. UDCA aids in dissolving cholesterol-based gallstones and enhances bile flow, thereby safeguarding liver cells from damage. It is widely regarded as a safe and effective treatment for managing cholestatic liver diseases.

There are two primary types of ursodeoxycholic acid: synthetic and extracted. Synthetic UDCA is a laboratory-produced form of the natural bile acid, designed to treat liver disorders and dissolve cholesterol gallstones by enhancing bile flow and minimizing liver cell damage. This formulation can be administered orally, via intravenous injection, or subcutaneously. It is mainly prescribed for conditions such as gallstones, primary biliary cholangitis, primary sclerosing cholangitis, and non-alcoholic fatty liver disease. Distribution channels include hospital pharmacies, retail outlets, and online platforms, serving end users such as hospitals, specialized clinics, research centers, and other institutions.

The ursodeoxycholic acid market research report is one of a series of new reports from The Business Research Company that provides ursodeoxycholic acid market statistics, including the ursodeoxycholic acid industry's global market size, regional shares, competitors with the ursodeoxycholic acid market share, detailed ursodeoxycholic acid market segments, market trends and opportunities, and any further data you may need to thrive in the ursodeoxycholic acid market. This ursodeoxycholic acid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ursodeoxycholic acid market size has grown rapidly in recent years. It will grow from $0.86 billion in 2024 to $0.96 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The expansion during the historical period can be attributed to factors such as the rising incidence of gallstone disease, increased awareness regarding liver health, higher diagnosis rates of primary biliary cholangitis, a greater shift toward non-invasive liver testing, and the aging global population.

The ursodeoxycholic acid market size is expected to see rapid growth in the next few years. It will grow to $1.44 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The projected growth will be driven by the rising burden of lifestyle-related health issues, growing reliance on hepatoprotective medications, increased need for long-term liver disease treatments, a robust pipeline of clinical trials focused on bile acid derivatives, and growing interest in less invasive surgical options. Key market trends in the coming years include advancements in targeted drug delivery methods, combining UDCA with other liver-protecting substances, new drug formulation strategies, development of bile acid analogs, and the emergence of RNA-based therapies aimed at liver regeneration.

The growing prevalence of liver diseases is anticipated to drive the expansion of the ursodeoxycholic acid market in the coming years. Liver diseases encompass various conditions that hinder the liver's normal function, such as infections, inflammation, fatty liver, cirrhosis, and liver cancer. One of the key contributors to this increase in liver-related conditions is the rising level of alcohol consumption, as prolonged excessive drinking can cause significant liver damage. Ursodeoxycholic acid plays a crucial role in treating liver diseases by enhancing bile flow and decreasing the levels of toxic bile acids, which makes it particularly effective in managing conditions like primary biliary cholangitis. It helps improve patient outcomes by slowing the progression of liver damage and aiding in the dissolution of cholesterol gallstones, thereby boosting the overall effectiveness of treatments. For example, in April 2024, the Office for Health Improvement and Disparities, a UK-based government department, reported 6,664 premature deaths from liver disease among males and 3,929 among females, reflecting a 22.8% increase for males and a 33.1% increase for females compared to previous years. This surge in liver disease cases is contributing to the growth of the ursodeoxycholic acid market.

Leading companies in the ursodeoxycholic acid (UDCA) market are increasingly developing advanced therapies, such as bile acid derivatives, to improve the treatment of liver diseases, particularly cholestatic liver disorders. Bile acid derivatives are chemically modified forms of bile acids designed to support liver function and manage various liver conditions. For instance, in November 2024, Nora Pharma Inc., a pharmaceutical company based in Canada, introduced a generic version of Ursodiol (ursodeoxycholic acid) aimed at treating cholestatic liver diseases, including primary biliary cholangitis (PBC). This medication is used to enhance liver function and decelerate liver damage progression, especially when administered early in the disease course. Additionally, it helps dissolve and prevent cholesterol gallstones by altering bile composition and reducing toxic bile acid levels.

In November 2022, Sunshine Biopharma Inc., a pharmaceutical company based in the United States, acquired Nora Pharma Inc. for an undisclosed sum. Through this acquisition, Sunshine Biopharma intends to diversify its revenue sources, strengthen its presence in the generic and biosimilar drug sectors, and make strides toward becoming a fully integrated pharmaceutical company. Nora Pharma Inc., headquartered in Canada, markets ursodeoxycholic acid under the brand name NRA-Ursodiol.

Major players in the ursodeoxycholic acid market are Mankind Pharma Pvt. Ltd, Abbott Healthcare Pvt. Ltd., Shandong Octagon Chemicals Limited, J.S.C. Grindeks, Arch Pharmalabs, Ind Swift Laboratories Ltd., Symbiotec Pharmalab, Suzhou Tianlu Bio-pharmaceutical Co. Ltd, Zeal MediPharma, Prodotti Chimici e Alimentari S.P.A., Mitsubishi Tanabe Pharma Corporation, ICE Pharma Inc, Xi'an Tian Guangyuan Biotech Co. Ltd, Aamorb Pharmaceuticals Inc., Axplora Inc, Octavius Pharma Pvt. Ltd, Sichuan Elixir Pharmaceutical Co. Ltd, Signova Pharma Pvt. Ltd., Sinoway Industrial Co. Ltd, and Valence Labs Pvt. Ltd.

North America was the largest region in the ursodeoxycholic acid market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ursodeoxycholic acid report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ursodeoxycholic acid market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ursodeoxycholic acid market consists of sales of ursodiol tablets, ursodeoxycholic acid capsules, suspensions, injectables, and combination drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ursodeoxycholic Acid Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ursodeoxycholic acid market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for ursodeoxycholic acid ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ursodeoxycholic acid market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Ursodeoxycholic Acid Market Characteristics

3. Ursodeoxycholic Acid Market Trends And Strategies

4. Ursodeoxycholic Acid Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Ursodeoxycholic Acid Growth Analysis And Strategic Analysis Framework

6. Ursodeoxycholic Acid Market Segmentation

7. Ursodeoxycholic Acid Market Regional And Country Analysis

8. Asia-Pacific Ursodeoxycholic Acid Market

9. China Ursodeoxycholic Acid Market

10. India Ursodeoxycholic Acid Market

11. Japan Ursodeoxycholic Acid Market

12. Australia Ursodeoxycholic Acid Market

13. Indonesia Ursodeoxycholic Acid Market

14. South Korea Ursodeoxycholic Acid Market

15. Western Europe Ursodeoxycholic Acid Market

16. UK Ursodeoxycholic Acid Market

17. Germany Ursodeoxycholic Acid Market

18. France Ursodeoxycholic Acid Market

19. Italy Ursodeoxycholic Acid Market

20. Spain Ursodeoxycholic Acid Market

21. Eastern Europe Ursodeoxycholic Acid Market

22. Russia Ursodeoxycholic Acid Market

23. North America Ursodeoxycholic Acid Market

24. USA Ursodeoxycholic Acid Market

25. Canada Ursodeoxycholic Acid Market

26. South America Ursodeoxycholic Acid Market

27. Brazil Ursodeoxycholic Acid Market

28. Middle East Ursodeoxycholic Acid Market

29. Africa Ursodeoxycholic Acid Market

30. Ursodeoxycholic Acid Market Competitive Landscape And Company Profiles

31. Ursodeoxycholic Acid Market Other Major And Innovative Companies

32. Global Ursodeoxycholic Acid Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ursodeoxycholic Acid Market

34. Recent Developments In The Ursodeoxycholic Acid Market

35. Ursodeoxycholic Acid Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기